Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

CompletedOBSERVATIONAL
Enrollment

1,247

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DEVICE

TheraSphere

Participants will receive treatment with TheraSphere in accordance with Instructions for Use

Trial Locations (37)

29609

Centre Hospitalier Régional et Universitaire de Brest, Brest

33000

Institut Bergonié, Bordeaux

66046

Centre Hospitalier de Perpignan, Perpignan

76038

Hôpital Henri Mondor, Créteil

94275

Bicêtre Hôpital, Le Kremlin-Bicêtre

94800

Hopital Paul Brousse, Villejuif

94805

Intstitut Gustave Roussy, Villejuif

Unknown

CHU Amiens, Amiens

CHU, Angers, Angers

CHU Jean Minjoz, Besançon

Hôpital Haut Leveque, Bordeaux

Centre George-Francois Leclerc, Dijon

CHU Dijon Bourgogne, Dijon

CHU Michallon, Grenoble

CHU Lille, Lille

Centre Leon Berard, Lyon

Hopital de la Croix-Rousse, Lyon

Hopital Edouard Herriot, Lyon

CHU de la Timone, Marseille

Institut Paoli Calmettes, Marseille

CHU Saint Eloi, Montpellier

CHU Brabois Adultes, Nancy

CHU Site Hotel Dieu, Nantes

CHU de l'Archet, Nice

CHU de Nîmes, Hôpital Carremeau, Nîmes

Hopital Beaujon, Paris

Hôpital Cochin, APHP, Paris

Hôpital Saint-Louis, Paris

Hopital Lyon Sud, Pierre-Bénite

CHU La Milétrie, Poitiers

Centre Eugene Marquis, Rennes

Centre Henri Becquerel, Rouen

CHU Rouen, Rouen

Centre Hospitalier Universitaire de St Etienne, Saint-Priest-en-Jarez

CHU deHautepierre, Strasbourg

Nouvel Hopital Civil, Strasbourg

CHU Rangueil, Toulouse

Sponsors
All Listed Sponsors
collaborator

Biocompatibles UK Ltd

INDUSTRY

lead

Boston Scientific Corporation

INDUSTRY